Yann Mazabraud
Vermögen: 7 Mio $ am 30.06.2026
Vermögen: 7 Mio $ am 30.06.2026
Yann Mazabraud is Executive Vice President & Head-International at Rhythm Pharmaceuticals, Inc. since 2020.
Former roles include General Manager-US & Head-North America at Genzyme Corp.
from 2016 to 2017, Head-Latin America at Genzyme Therapeutics Ltd., and Chief Commercial Officer & Head-International at Trevi Therapeutics, Inc. from 2017 to 2020.
Education includes a graduate degree from Groupe de Sup de Co La Rochelle.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 27.04.2026 | 66’030 ( 0.1% ) | 7 Mio $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05.10.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
| TREVI THERAPEUTICS, INC. | Corporate Officer/Principal | 03.10.2020 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01.10.2017 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Groupe de Sup de Co La Rochelle
Groupe de Sup de Co La Rochelle Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment for cough conditions | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen